Current Environment: Production

617-632-5508
Dana-Farber/Boston Children's Cancer and Blood Disorders Center
Location Page
/centers/cancer-and-blood-disorders-center

Education

Medical School

Yale University School of Medicine

1992, New Haven, CT

Internship

Pediatrics

Boston Children's Hospital

1993, Boston, MA

Residency

Pediatrics

Boston Combined Residency Program (BCRP)

1995, Boston, MA

Fellowship

Pediatric Hematology-Oncology

Dana-Farber/Boston Children's Cancer and Blood Disorders Center

1997, Boston, MA

Publications

  1. Wilms Tumor in Children with AMER1/WTX Germline Pathogenic Variants: A Multicenter Case Series. Pediatr Blood Cancer. 2025 May 21; e31798. View Abstract

  2. Remaining Challenges in the Treatment of Relapsed Wilms Tumor: Children's Oncology Group and International Society of Paediatric Oncology Perspectives. Pediatr Blood Cancer. 2025 May 14; e31790. View Abstract

  3. Associations of Patient Age, Tumor Nephrectomy Weight, and Tumor Diameter with Event-Free and Overall Survival in Stage I or II Favorable Histology Wilms Tumor: A Pooled Analysis of Children's Oncology Group Studies AREN0532 and AREN03B2. Ann Surg. 2025 Apr 11. View Abstract

  4. Hallmark discoveries in the biology of non-Wilms tumour childhood kidney cancers. Nat Rev Urol. 2025 Jan 29. View Abstract

  5. Treatment of focal anaplastic Wilms tumor: A report from the Children's Oncology Group AREN0321 and AREN03B2 studies. Cancer. 2025 Jan 15; 131(2):e35713. View Abstract

  6. Rhabdoid Tumor of the Kidney and Soft Tissues: Results from National Wilms Tumor Study-5 and Children's Oncology Group Study AREN0321. Pediatr Blood Cancer. 2025 Mar; 72(3):e31490. View Abstract

  7. Outcomes of relapsed favorable-histology Wilms tumor in non-clinical trial setting. Pediatr Blood Cancer. 2025 01; 72(1):e31347. View Abstract

  8. BRAF Exon 15 Mutations in the Evaluation of Well-Differentiated Epithelial Nephroblastic Neoplasms in Children: A Report From the Children's Oncology Group Study AREN03B2. Arch Pathol Lab Med. 2024 Oct 01; 148(10):e362-e366. View Abstract

  9. Author Correction: Molecular profiling of 888 pediatric tumors informs future precision trials and data-sharing initiatives in pediatric cancer. Nat Commun. 2024 Aug 22; 15(1):7218. View Abstract

  10. Response of bilateral Wilms tumor to chemotherapy suggests histologic subtype and guides treatment. J Natl Cancer Inst. 2024 Aug 01; 116(8):1230-1237. View Abstract

  11. Molecular profiling of 888 pediatric tumors informs future precision trials and data-sharing initiatives in pediatric cancer. Nat Commun. 2024 Jul 11; 15(1):5837. View Abstract

  12. Long-term outcomes and patterns of relapse in patients with bilateral Wilms tumor or bilaterally predisposed unilateral Wilms tumor, a report from the COG AREN0534 study. Int J Cancer. 2024 Nov 15; 155(10):1824-1831. View Abstract

  13. Anaplastic sarcoma of the kidney (DICER1-sarcoma of the kidney): A report from the International Pleuropulmonary Blastoma/DICER1 Registry. Pediatr Blood Cancer. 2024 Aug; 71(8):e31090. View Abstract

  14. Bilateral Wilms tumor with anaplasia: A report from the Children's Oncology Group Study AREN0534. Pediatr Blood Cancer. 2024 Jul; 71(7):e30981. View Abstract

  15. Targeting TRIP13 in favorable histology Wilms tumor with nuclear export inhibitors synergizes with doxorubicin. Commun Biol. 2024 04 08; 7(1):426. View Abstract

  16. Race and Ethnic Group Enrollment and Outcomes for Wilms Tumor: Analysis of the Current Era Children's Oncology Group Study, AREN03B2. J Am Coll Surg. 2024 Apr 01; 238(4):733-749. View Abstract

  17. Treatment and outcomes of clear cell sarcoma of the kidney: A report from the Children's Oncology Group studies AREN0321 and AREN03B2. Cancer. 2024 Jul 01; 130(13):2361-2371. View Abstract

  18. Genetic and epigenetic features of bilateral Wilms tumor predisposition in patients from the Children's Oncology Group AREN18B5-Q. Nat Commun. 2023 12 18; 14(1):8006. View Abstract

  19. Treatment of children with favorable histology Wilms tumor with extrapulmonary metastases: A report from the COG studies AREN0533 and AREN03B2 and NWTSG study NWTS-5. Cancer. 2024 03 15; 130(6):947-961. View Abstract

  20. Prognostic impact of lymph node involvement and loss of heterozygosity of 1p or 16q in stage III favorable histology Wilms tumor: A report from Children's Oncology Group Studies AREN03B2 and AREN0532. Cancer. 2024 03 01; 130(5):792-802. View Abstract

  21. Hallmark discoveries in the biology of Wilms tumour. Nat Rev Urol. 2024 03; 21(3):158-180. View Abstract

  22. Children's Oncology Group's 2023 blueprint for research: Renal tumors. Pediatr Blood Cancer. 2023 09; 70 Suppl 6:e30586. View Abstract

  23. Severe Hepatopathy in National Wilms Tumor Studies 3-5: Prevalence, Clinical Features, and Outcomes After Reintroduction of Chemotherapy. J Clin Oncol. 2023 09 10; 41(26):4247-4256. View Abstract

  24. A single-institution pediatric and young adult interventional oncology collaborative: Novel therapeutic options for relapsed/refractory solid tumors. Cancer Med. 2023 06; 12(12):13300-13308. View Abstract

  25. Tolerability of ifosfamide-containing regimen in patients with high-risk renal and INI-1-deficient tumors. Pediatr Blood Cancer. 2023 08; 70(8):e30422. View Abstract

  26. The Genetic and Epigenetic Features of Bilateral Wilms Tumor Predisposition: A Report from the Children's Oncology Group AREN18B5-Q Study. Res Sq. 2023 Mar 16. View Abstract

  27. Late Health Outcomes Among Survivors of Wilms Tumor Diagnosed Over Three Decades: A Report From the Childhood Cancer Survivor Study. J Clin Oncol. 2023 05 10; 41(14):2638-2650. View Abstract

  28. The varied spectrum of nephroblastomatosis, nephrogenic rests, and Wilms tumors: Review of current definitions and challenges of the field. Pediatr Blood Cancer. 2023 05; 70 Suppl 2:e30162. View Abstract

  29. Genetic changes associated with relapse in favorable histology Wilms tumor: A Children's Oncology Group AREN03B2 study. Cell Rep Med. 2022 06 21; 3(6):100644. View Abstract

  30. Circulating Tumor DNA as a Biomarker in Patients With Stage III and IV Wilms Tumor: Analysis From a Children's Oncology Group Trial, AREN0533. J Clin Oncol. 2022 09 10; 40(26):3047-3056. View Abstract

  31. White paper: Oncofertility in pediatric patients with Wilms tumor. Int J Cancer. 2022 09 15; 151(6):843-858. View Abstract

  32. ASO Video Abstract: Kidney Preservation and Wilms Tumor Development in Children with Diffuse Hyperplastic Perilobar Nephroblastomatosis-A Report from the Children's Oncology Group Study AREN0534. Ann Surg Oncol. 2022 05; 29(5):3262-3263. View Abstract

  33. Outcomes based on histopathologic response to preoperative chemotherapy in children with bilateral Wilms tumor: A prospective study (COG AREN0534). Cancer. 2022 07 01; 128(13):2493-2503. View Abstract

  34. Authors' Reply to the Letter to the Editor by Daniel M. Green. J Natl Compr Canc Netw. 2022 03; 20(3):xlvii-xlviii. View Abstract

  35. Kidney Preservation and Wilms Tumor Development in Children with Diffuse Hyperplastic Perilobar Nephroblastomatosis: A Report from the Children's Oncology Group Study AREN0534. Ann Surg Oncol. 2022 May; 29(5):3252-3261. View Abstract

  36. Impact of the First Generation of Children's Oncology Group Clinical Trials on Clinical Practice for Wilms Tumor. J Natl Compr Canc Netw. 2021 08 01; 19(8):978-985. View Abstract

  37. Wilms Tumor (Nephroblastoma), Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021 08 01; 19(8):945-977. View Abstract

  38. Haplotype-resolved germline and somatic alterations in renal medullary carcinomas. Genome Med. 2021 07 14; 13(1):114. View Abstract

  39. Author Correction: PGBD5 promotes site-specific oncogenic mutations in human tumors. Nat Genet. 2020 Nov; 52(11):1265. View Abstract

  40. Phase I/II Study of Stereotactic Body Radiation Therapy for Pulmonary Metastases in Pediatric Patients. Adv Radiat Oncol. 2020 Nov-Dec; 5(6):1267-1273. View Abstract

  41. A prospective study of pediatric and adolescent renal cell carcinoma: A report from the Children's Oncology Group AREN0321 study. Cancer. 2020 12 01; 126(23):5156-5164. View Abstract

  42. The use of interval-compressed chemotherapy with the addition of vincristine, irinotecan, and temozolomide for pediatric patients with newly diagnosed desmoplastic small round cell tumor. Pediatr Blood Cancer. 2020 10; 67(10):e28559. View Abstract

  43. Results of Treatment for Patients With Multicentric or Bilaterally Predisposed Unilateral Wilms Tumor (AREN0534): A report from the Children's Oncology Group. Cancer. 2020 08 01; 126(15):3516-3525. View Abstract

  44. DICER1-associated central nervous system sarcoma in children: comprehensive clinicopathologic and genetic analysis of a newly described rare tumor. Mod Pathol. 2020 10; 33(10):1910-1921. View Abstract

  45. Outcome analysis of stage I epithelial-predominant favorable-histology Wilms tumors: A report from Children's Oncology Group study AREN03B2. Cancer. 2020 06 15; 126(12):2866-2871. View Abstract

  46. Imaging Characteristics of Nephrogenic Rests Versus Small Wilms Tumors: A Report From the Children's Oncology Group Study AREN03B2. AJR Am J Roentgenol. 2020 05; 214(5):987-994. View Abstract

  47. Activity of Vincristine and Irinotecan in Diffuse Anaplastic Wilms Tumor and Therapy Outcomes of Stage II to IV Disease: Results of the Children's Oncology Group AREN0321 Study. J Clin Oncol. 2020 05 10; 38(14):1558-1568. View Abstract

  48. Genomic and Immunologic Characterization of INI1-Deficient Pediatric Cancers. Clin Cancer Res. 2020 06 15; 26(12):2882-2890. View Abstract

  49. 50 Years Ago in TheJournal ofPediatrics: 50 years of progress in renal cell carcinoma: From case reports to targeted therapy. J Pediatr. 2020 03; 218:120. View Abstract

  50. Augmentation of Therapy for Combined Loss of Heterozygosity 1p and 16q in Favorable Histology Wilms Tumor: A Children's Oncology Group AREN0532 and AREN0533 Study Report. J Clin Oncol. 2019 10 20; 37(30):2769-2777. View Abstract

  51. Prohibitin is a prognostic marker and therapeutic target to block chemotherapy resistance in Wilms' tumor. JCI Insight. 2019 08 08; 4(15). View Abstract

  52. Treatment of stage I anaplastic Wilms' tumour: a report from the Children's Oncology Group AREN0321 study. Eur J Cancer. 2019 09; 118:58-66. View Abstract

  53. Reply to L. Xie et al. J Clin Oncol. 2019 05 10; 37(14):1264-1265. View Abstract

  54. Renal medullary carcinomas depend upon SMARCB1 loss and are sensitive to proteasome inhibition. Elife. 2019 03 12; 8. View Abstract

  55. Impact of Surveillance Imaging Modality on Survival After Recurrence in Patients With Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group. J Clin Oncol. 2018 Oct 18; JCO1800076. View Abstract

  56. Reply to D.M. Green. J Clin Oncol. 2018 Sep 13; JCO1800659. View Abstract

  57. Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma. Clin Genitourin Cancer. 2019 02; 17(1):1-6. View Abstract

  58. Detection of Somatic Structural Variants Enables Quantification and Characterization of Circulating Tumor DNA in Children With Solid Tumors. JCO Precis Oncol. 2018; 2018. View Abstract

  59. The classification of pediatric and young adult renal cell carcinomas registered on the children's oncology group (COG) protocol AREN03B2 after focused genetic testing. Cancer. 2018 08; 124(16):3381-3389. View Abstract

  60. Treatment of Stage IV Favorable Histology Wilms Tumor With Lung Metastases: A Report From the Children's Oncology Group AREN0533 Study. J Clin Oncol. 2018 06 01; 36(16):1564-1570. View Abstract

  61. Reply to B. Zhang et al. J Clin Oncol. 2018 05 10; 36(14):1454-1455. View Abstract

  62. Outcome and Prognostic Factors in Stage III Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group Study AREN0532. J Clin Oncol. 2018 01 20; 36(3):254-261. View Abstract

  63. Erratum: PGBD5 promotes site-specific oncogenic mutations in human tumors. Nat Genet. 2017 09 27; 49(10):1558. View Abstract

  64. Results of the First Prospective Multi-institutional Treatment Study in Children With Bilateral Wilms Tumor (AREN0534): A Report From the Children's Oncology Group. Ann Surg. 2017 09; 266(3):470-478. View Abstract

  65. Imaging of renal medullary carcinoma in children and young adults: a report from the Children's Oncology Group. Pediatr Radiol. 2017 Nov; 47(12):1615-1621. View Abstract

  66. Renal Medullary Carcinoma: Establishing Standards in Practice. J Oncol Pract. 2017 07; 13(7):414-421. View Abstract

  67. PGBD5 promotes site-specific oncogenic mutations in human tumors. Nat Genet. 2017 Jul; 49(7):1005-1014. View Abstract

  68. Clinical Outcome and Biological Predictors of Relapse After Nephrectomy Only for Very Low-risk Wilms Tumor: A Report From Children's Oncology Group AREN0532. Ann Surg. 2017 04; 265(4):835-840. View Abstract

  69. Synchronous occurrence of acute lymphoblastic leukemia and wilms tumor in two patients: underlying etiology and combined treatment plan. Pediatr Blood Cancer. 2017 05; 64(5). View Abstract

  70. Association of Chromosome 1q Gain With Inferior Survival in Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group. J Clin Oncol. 2016 09 10; 34(26):3189-94. View Abstract

  71. Surgical protocol violations in children with renal tumors provides an opportunity to improve pediatric cancer care: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2016 11; 63(11):1905-10. View Abstract

  72. Pediatric cystic nephromas: distinctive features and frequent DICER1 mutations. Hum Pathol. 2016 Feb; 48:81-7. View Abstract

  73. Advances in Wilms Tumor Treatment and Biology: Progress Through International Collaboration. J Clin Oncol. 2015 Sep 20; 33(27):2999-3007. View Abstract

  74. Characterization of adolescent and pediatric renal cell carcinoma: A report from the Children's Oncology Group study AREN03B2. Cancer. 2015 Jul 15; 121(14):2457-64. View Abstract

  75. Comparison of diagnostic performance of CT and MRI for abdominal staging of pediatric renal tumors: a report from the Children's Oncology Group. Pediatr Radiol. 2015 Feb; 45(2):166-72. View Abstract

  76. Feasibility of using CT volume as a predictor of specimen weight in a subgroup of patients with low risk Wilms tumors registered on COG Study AREN03B2: implications for central venous catheter placement. J Pediatr Urol. 2014 Oct; 10(5):969-73. View Abstract

  77. DICER1 mutations in childhood cystic nephroma and its relationship to DICER1-renal sarcoma. Mod Pathol. 2014 Sep; 27(9):1267-80. View Abstract

  78. Inter-rater reliability of surgical reviews for AREN03B2: a COG renal tumor committee study. J Pediatr Surg. 2014 Jan; 49(1):154-8; discussion 158. View Abstract

  79. Uncle Sam and your job options. Considering your next career move? Consider the tax implications. Del Med J. 2013 May; 85(5):147-9. View Abstract

  80. Primary nephrectomy and intraoperative tumor spill: report from the Children's Oncology Group (COG) renal tumors committee. J Pediatr Surg. 2013 Jan; 48(1):34-8. View Abstract

  81. Children's Oncology Group's 2013 blueprint for research: renal tumors. Pediatr Blood Cancer. 2013 Jun; 60(6):994-1000. View Abstract

  82. Detection of preoperative wilms tumor rupture with CT: a report from the Children's Oncology Group. Radiology. 2013 Feb; 266(2):610-7. View Abstract

  83. Barriers to the enrollment of children in the Children's Oncology Group study of very low risk Wilms tumor: a report from the Children's Oncology Group. J Pediatr Hematol Oncol. 2011 Oct; 33(7):521-3. View Abstract

  84. The impact of surveillance imaging on overall survival in patients with recurrent Wilms tumor: A report from the Children's Oncology Group. J Clin Oncol. 2011 May 20; 29(15_suppl):9536. View Abstract

  85. Topotecan is active against Wilms' tumor: results of a multi-institutional phase II study. J Clin Oncol. 2007 Jul 20; 25(21):3130-6. View Abstract

  86. Pediatric Oncologic Emergencies. Nathan & Oski's Hematology Textbook of Infancy and Childhood. 2007; In Press.

  87. The effects of postoperative pain and its management on postoperative cognitive dysfunction. Am J Geriatr Psychiatry. 2007 Jan; 15(1):50-9. View Abstract

  88. Exploring the psychological underpinnings of the moral mandate effect: motivated reasoning, group differentiation, or anger? J Pers Soc Psychol. 2006 Apr; 90(4):629-43. View Abstract

  89. Postoperative delirium: the importance of pain and pain management. Anesth Analg. 2006 Apr; 102(4):1267-73. View Abstract

  90. Universal session-level change processes in an early session of psychotherapy: path models. J Consult Clin Psychol. 2006 Apr; 74(2):327-36. View Abstract

  91. Section Editor, Oncology. Pediatric Hospitalist Textbook, Chiang. 2006.

  92. Oncologic Emergencies Chapter. Pediatric Hospitalist Textbook, Chiang. 2006.

  93. Section Editor, Oncology. Pediatric Hospitalist Textbook. 2006.

  94. The Safety of Oral Magnesium Pidolate in Children with Hemoglobin SC Disease. Presented at the 28th Annual Meeting of the National Sickle Cell Disease Program. 2005.

  95. Multiple micronutrient deficiencies in a child fed an elemental formula. J Pediatr Gastroenterol Nutr. 2001 Nov; 33(5):602-5. View Abstract

  96. Clinical Practice Guidelines for the treatment of patients with Sickle Cell Disease, on the topic of Acute Chest. 2001.

  97. Multiple Micronutrient Deficiencies in a Child Fed an Elemental Formula. Journal of Pediatric Oncology. 2001; (5):602-605.

  98. Clinical Practice Guidelines on the treatment of patients with Sickle Cell Disease, on the topic of Transfusion. 2001.

  99. Clinical Practice Guidelines for the treatment of patients with Sickle Cell Disease, on the topic of Pain. 2000.

  100. Clinical Practice Guidelines for the treatment of patients with Sickle Cell Disease, on the topic of Splenic Sequestration. 2000.

  101. Clinical Practice Guidelines for the treatment of Fever in Sickle Cell Disease. 2000.

  102. Clinical Practice Guidelines for the treatment of Fever and Neutropenia. 2000.

  103. Clinical Practice Guidelines for the treatment of patients with Sickle Cell Disease, on the topic of Fever. 2000.

  104. Clinical Practice Guidelines for the treatment of patients with Sickle Cell Disease, on the topic of Routine Health Maintainence and Priapism. 2000.

  105. Clinical Practice Guidelines for the treatment of Pain in Sickle Cell Disease. 2000.

  106. Multiple Mechanisms of Cell Injury in the Gastric Mucosa. Federal Proceedings. 1991; 46:1152.

  107. Biochemical Characterization of a Boving Corneal Angiogenesis Inhibitor. 1991.

  108. Fluorogenic Assay of Proteinase Activity in Developing Rat Enamel. Journal of Dental Research. 1989; 68:239.

  109. Abundant Occurrence of Gamma-Carboxyglutamic Acid-Containing Peptides in the Gastropod Family. Current Advances in Vitamin K Research. Ed. John Suttie. 1988.

  110. An examination of the Vitamin K Cycle: Phenytoin Interference in K-dependent Carboxylase Activity. 1985.

Education

Medical School

David Geffen School of Medicine at UCLA

2008, Los Angeles, CA

Internship

Pediatrics

Lucile Packard Children’s Hospital at Stanford University

2009, Palo Alto, CA

Residency

Pediatrics

Lucile Packard Children’s Hospital at Stanford University

2011, Palo Alto, CA

Fellowship

Clinical Ethics

MacLean Center for Clinical Medical Ethics, University of Chicago

2012, Chicago, IL

Fellowship

Pediatric Hematology/Oncology

Boston Children’s Hospital/Dana-Farber Cancer Institute

2015, Boston, MA

Fellowship

Health Services Research

Harvard Medical School

2016, Boston, MA

Graduate School

MPH

Harvard T.H. Chan School of Public Health

2016, Boston, MA

Publications

Education

Medical School

Kansas University Medical School

1967, Kansas City, MO

Internship

Boston Children's Hospital

1968, Boton, MA

Residency

Boston Children's Hospital

1969, Boston, MA

Fellowship

Boston Children's Hospital

1973, Boston, MA

Publications

Education

Medical School

Duke University School of Medicine

Durham, NC

Residency

Pediatrics

Duke University School of Medicine

Durham, NC

Fellowship

Pediatric Hematology-Oncology

Boston Children's Hospital/Dana-Farber Cancer Institute

Boston, MA

Publications

Education

Undergraduate School

Loyola University

Chicago, IL

Medical School

Central American Health Science University

2010, Ladyville, Belize

Residency

Penn State Health Milton S. Hershey Medical Center

2014, Hershey, PA

Fellowship

Penn State Health Milton S. Hershey Medical Center

2017, Hershey, PA

Fellowship

Bone Marrow Transplant

Cancer and Blood Diseases Institute at Cincinnati Children's Hospital

2019, Cincinnati, OH

Publications

Education

Medical School

Medical College and Hospital, Kolkata / Calcutta Medical College

2004, Kolkata, India

Residency

SUNY Downstate College of Medicine

2008, Brooklyn, NY

Graduate School

MS, Clinical and Translational Science

Mayo Clinic School of Graduate Medical Education

2011, Rochester, MN

Fellowship

Pediatric Hematology/Oncology

Mayo Clinic

2011, Rochester, MN

Fellowship

Pediatric Thrombosis/Hemostasis

The Hospital for Sick Children

2013, Toronto, Ontario, Canada

Publications

Education

Undergraduate School

University of Wisconsin

Madison, WI

Graduate School

Harvard School of Graduate Education

Boston, MA

Graduate School

Bioethics

University of Pennsylvania Center for Bioethics

Philadelphia, PA

Medical School

University of Pennsylvania School of Medicine

Philadelphia, PA

Publications

Education

Medical School

Harvard Medical School

2008, Boston, MA

Residency

Boston Combined Residency Program (BCRP)

2011, Boston, MA

Fellowship

Pediatric Hematology-Oncology

Boston Children's Hospital/Dana-Farber Cancer Institute

2014, Boston, MA

Publications

Education

Undergraduate School

Boston College

1985, Boston, MA

Medical School

SUNY at Stony Brook School of Medicine

1989, Stony Brook, NY

Internship

Pediatrics

Children's National Medical Center

1990, Washington, DC

Residency

Pediatrics

Children's National Medical Center

1992, Washington, DC

Fellowship

Pediatric Hematology-Oncology

Children's National Medical Center

1995, Washington, DC

Publications

Education

Medical School

Albert Einstein College of Medicine

2011, Bronx, NY

Residency

Boston Children's Hospital/Boston Medical Center

2014, Boston, MA

Fellowship

Dana-Farber Cancer Institute/Boston Children's Hospital

2018, Boston, MA

Publications
Subscribe to Dana-Farber/Boston Children's Cancer and Blood Disorders Center

Talk to Lesley

If this is a medical emergency, please dial 9-1-1. This application should not be used in an emergency. This chat is being transmitted via a secure connection.

Hi! My name is Lesley. I am a virtual agent programmed to help you. If you would like to speak to a live agent, please call 617-355-6000.

I am unable to answer specific questions regarding your child's case, including appointments and conditions/diagnosis. Please contact your physician's office.

Quick links:

- MyChildrens Portal
- Global Services
- Find a Doctor
- Find a Location
- Programs and Services